---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025872"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:24:28.007479+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics Q2 2024 net loss $2.7M; AJ201 trial topline data expected H2 2024

## Summary
- Cash and equivalents $4.9M at June 30, 2024, up from $1.8M at Dec 31, 2023.
- Net loss $2.7M ($6.43/share) for Q2 2024, compared to $4.0M ($38.74/share) in Q2 2023.
- AJ201 Phase 1b/2a SBMA trial last patient visit complete; topline data expected in H2 2024.
- Raised $4.4M gross proceeds from April 2024 warrant exercise; 1-for-75 reverse stock split effected.
- Regained Nasdaq compliance in May 2024 after reverse split.

## SEC filing metadata
- accession: 0001437749-24-025872
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774924025872/0001437749-24-025872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774924025872/atxi20240520_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025872
- JSON: https://secwatch.observer/filing/0001437749-24-025872.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.